Meet the Author
Chief Scientific Officer
Dr. Yannis Jemiai has a pivotal role within Cytel as Chief Scientific Officer. He has oversight for the corporate-level Scientific Agenda, which includes establishing research portfolios in Bayesian, small sample, and other flexible designs as well as complex innovative designs including adaptive trials, master protocols, and MAMS. Yannis also has an extensive portfolio of research in adaptive trial design, financial and pharmaceutical strategy, decision theory, and regulatory affairs. His own research has been published in numerous statistical journals. Yannis earned his Ph.D. from Harvard University, an M.P.H. from Columbia University, and a B.A. in Molecular and Cellular Biology also from Harvard.